They still haven't officially announced date of 3Q conference call ... I know the friar likes Veterans day.
Looks like they simply do not know how to effectively unwind their bogus 1 product business. This business model is like an aging prostitute who is running out of tricks....
Yes, Now is when they will initiate a stock buyback. On this weakness... Absolutely buy at the open tomorrow.
Cleveland BioLabs, Inc., a clinical-stage biotechnology company, engages in the research, development, and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation, and counteract the genotoxic effects of radio- and chemotherapies for oncology patients. Its lead drug is Entolimod, which is being developed for radiation countermeasure and cancer treatment. The company's products candidates also include CBL0102, which is undergoing a Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and CBL0137, which is in multi-center, single agent, dose escalation Phase I study of the oral formulation in subjects with advanced solid tumors. In addition, it has pre-clinical stage products candidates, such as CBLB612, an inducer and mobilizer of hematopoietic stem cells; Revercom, a cancer drug candidate comprising a liposome-packaged proprietary small molecule named Reversan; Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin; Arkil, a prospective treatment for prostate cancer; Antimycon, a proprietary small molecule lead compound generated to selectively target and inactivate oncoproteins of the Myc family; and Xenomycin family of compounds, which have a range of potential applications as antimicrobial and anti-fungal agents. The company has license agreements and collaborations with the Cleveland Clinic, Roswell Park Cancer Institute, the Childrens Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Search Yahoo! for:
More on Cleveland BioLabs, Inc.
Probably they try to exercise there buyback at the lowest possible prices, and not until. no reason for this to trade lower.
yea bro, go in and out of ugaz. can have fun all winter long. pay attention to cold fronts from Canada, weekly forcasts of temps. nat gas inv. comes out Thursdays. dgaz, of course is the inverse... gl
The same nonsense was published in late may early june. remember ? late may, the manipulated wind down from 2 bucks...... you guys ought to stay away from biotech and trade real companies.